Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Casimiroin is a naturally occurring small molecule classified as a quinoline derivative. It is isolated from the plant Casimiroa edulis and has also been reported in Dictyoloma vandellianum. Casimiroin functions as an inhibitor of quinone reductase 2 (NQO2), an enzyme involved in cellular redox regulation and detoxification pathways. Preclinical studies have shown that casimiroin and its analogues can inhibit both quinone reductase 2 and aromatase activity. These properties suggest potential chemopreventive or chemotherapeutic applications; however, there are no approved indications or clinical trials for this compound to date[1][2][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on casimiroin.